Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults - Garau,J.; Twynholm,M.; Garcia-Mendez,E.; Siquier,B.; Rivero,A. (J Antimicrob Chemother, 2003)